Insperity (NSP) Q2 2026 earnings review
Profitability Reverses Course, But Relies on Cost Cuts as Volume Decelerates
Insperity delivered a mixed Q2. Management's 'margin recovery' narrative is playing out at the bottom line, with Net Income reversing from a $5M loss last year to a $4M profit, and Adjusted EBITDA accelerating 13% YoY to $36M. However, this profitability was engineered almost entirely through an 8% reduction in operating expenses, not fundamental business expansion. Revenue grew a stable 2%, driven entirely by pricing increases (+3% per worksite employee) that masked a decelerating client volume. The core WSEE (worksite employee) metric shrank 1% YoY, and Q3 guidance indicates this contraction is accelerating.
🐂 Bull Case
Management successfully slashed operating expenses by 8% YoY to $211M. This strong cost discipline is actively restoring the bottom line even in a weak macro environment.
Revenue per WSEE increased 3% YoY to $1,838/month. The company is successfully passing along targeted price hikes and shedding lower-margin clients without triggering catastrophic churn.
🐻 Bear Case
Average paid WSEEs fell 1% in Q2 and are guided down ~2% for Q3. The strategy of sacrificing growth for margin is leaving the company with a contracting customer base.
Despite the bottom-line beat, gross profit actually declined 3% YoY as benefits costs per covered employee rose 5%. The 'margin recovery' has not yet fixed the core cost-of-delivery issue.
⚖️ Verdict: ⚪
Neutral. Insperity stopped the bleeding on the bottom line, which is commendable following a disastrous 2025. But achieving profit growth through aggressive OpEx cuts while the core customer base shrinks is a defensive maneuver, not a sustainable long-term growth engine.
Key Themes
Operating Expense Leverage Drives the Bottom Line
The primary driver of Q2's profitability beat was an 8% YoY reduction in operating expenses (down to $211M from $230M). This reflects the workforce realignments and restructuring actions taken in Q1. Management's ability to pull this lever proves they can stabilize earnings, even when top-line growth is stagnant.
Strategic Pricing Replaces Volume
With WSEE volumes down, Insperity leaned entirely on pricing for its 2% revenue growth. Revenue per WSEE per month grew 3% to $1,838. By strategically pushing price increases to offset inflation and actively non-renewing unprofitable clients, the company is curating a higher-quality, albeit smaller, revenue base.
HRScale and AI Innovation Pipeline
The strategic partnership with Workday (HRScale) remains the vital long-term catalyst to transition upmarket (150-5,000 employees). Operating expenses included $8M related to the Workday partnership in Q2 (down from $14M a year ago), indicating development costs are beginning to taper as the product moves toward broad monetization. Furthermore, the company continues its push into AI-driven proprietary 'copilot' agents to streamline internal operations and enhance client HR analytics.
Gross Profit Contradicts the Margin Recovery Narrative
While management touted 'meaningful progress' on margin recovery, the actual Gross Profit data tells a reversing story. Gross profit declined 3% YoY to $217M, and gross profit per WSEE fell 1% to $237. The culprit remains elevated benefit costs, which rose 5% per covered employee. The company's profitability fix is currently an OpEx story; the core unit economics of their health plans have not yet fully healed.
WSEE Contraction is Accelerating
Average WSEEs paid declined 1% YoY in Q2 to 305,764. More worryingly, Q3 guidance calls for 305,500 - 307,500 WSEEs, which represents a decelerating YoY drop of -1.7% to -2.3%. The combination of deliberately shedding unprofitable clients and a sluggish sales environment is shrinking the foundation of the business.
SMB Macro Sentiment Remains Weak
The broader macroeconomic environment for Small and Medium Businesses (SMBs) continues to act as a heavy anchor. Consistent with prior quarters, client net hiring is stagnant. Cautious business owners are limiting overtime, delaying expansions, and pausing hiring, which directly caps Insperity's organic growth.
Other KPIs
Benefits costs per covered employee rose 5% YoY in Q2. While slightly improved from the massive 9%+ spikes seen in mid-2025, this 5% inflation still outpaced the 3% increase in Revenue per WSEE. Until pricing growth outpaces benefit cost growth, gross margin compression will continue.
Adjusted cash (excluding funds held for tax withholdings and client prepayments) improved to $95M at the end of Q2, up from $57M at year-end 2025. The company drew $50M from its credit facility for working capital, bringing total debt to $419M, but liquidity remains stable.
Guidance
Decelerating. The implied midpoint represents a YoY decline of roughly 2.0%, which is a worsening trend compared to the 1.0% decline experienced in Q2. This signals that client churn and weak macro hiring will persist.
Accelerating. The wide range reflects the volatility of the new UnitedHealthcare contract (which back-loads claim reimbursements). The midpoint of $27.5M represents massive YoY growth over a very weak Q3 2025 ($10M).
Accelerating. Raised significantly from 2025's actual $1.03. Based on an assumed 36% effective tax rate, achieving this relies heavily on continued aggressive control of operating expenses in the back half of the year.
Key Questions
Gross Profit Timing
Operating expense cuts drove Q2 profitability, but gross profit still declined 3%. When exactly in the second half of 2026 do you expect the new UnitedHealthcare contract terms and pricing increases to finally flip gross profit growth to positive?
WSEE Floor
Guidance implies WSEE contraction will accelerate in Q3 (down ~2%). What is your internal modeling for when the WSEE base will hit a bottom and resume sequential, sustained organic growth?
HRScale Financial Impact
With Workday partnership expenses stepping down from $14M to $8M this quarter, when should investors expect HRScale to become a material, standalone contributor to top-line revenue rather than just a development cost?